A new clinical trial listing was recorded on October 9, 2026, concerning tirzepatide. The study, registered as NCT07868354, is titled "A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication." The trial is listed as Phase 1. Its current status is not yet recruiting. The study is designed to examine adults with overweight or obesity, with or without type 2 diabetes, who are switching from their current tirzepatide medication to a treatment referred to as zenagamtide. No results, efficacy data, or safety findings have been posted for this trial at this time. The listing reflects a planned study rather than completed research. Further details on enrollment criteria, timelines, and outcome measures are expected to be published as the trial progresses toward recruitment. Readers interested in tirzepatide's background, regulatory status, and general information can consult the compound overview for additional context.
Phase 1 Trial Planned for Switch From Tirzepatide to Zenagamtide
See the full tirzepatide overview
Source: https://clinicaltrials.gov/study/NCT07868354